Search

Displaying results 4811 - 4820 of 10000 in total
  1. Drug

    Etelcalcetide

    go.drugbank.com/drugs/DB12865
    ApprovedInvestigational

    Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. … Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.

    Categories: Calcium-sensing Receptor Agonist, Increased Calcium-sensing Receptor Sensitivity
  2. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.

  3. Drug

    AT3022

    go.drugbank.com/drugs/DB05172
    Experimental

    AT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.

  4. Drug

    PRO 2000

    go.drugbank.com/drugs/DB05385
    Investigational

    This medicine does not cure HIV infection or AIDS and is being studied to reduce the risk of passing the virus to other people. … It is being studied for the prevention of HIV infection and other sexually transmitted diseases.

  5. Drug

    Bismuth subcitrate potassium

    go.drugbank.com/drugs/DB09275
    ApprovedInvestigational

    A bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).

    Products: DE NOL, DE-NOL 300 MG TABLET, 60 ADET
  6. Drug

    Natural Killer Cell

    go.drugbank.com/drugs/DB15721
    Investigational

    NK Cells express features of innate immune responses, and respond to all molecules that appear to be foreign to the body. … Expansion involves the use of feeder cell line systems or bioreactors to enhance the number of NK cells with desired cytotoxicity.

  7. Drug

    HY10275

    go.drugbank.com/drugs/DB05079
    Experimental

    This dual-acting receptor activity and the lack of affinity for undesired off- target receptors are thought to account for the compounds excellent efficacy and tolerability profile. … HY10275 was rationally designed to "let you sleep" rather than depress the entire brain to "make you sleep."

  8. Drug

    Poliglusam

    go.drugbank.com/drugs/DB11234
    ApprovedInvestigational

    Naturally-occuring poliglusam is found in the cell walls of fungi, soil and sediments where it is produced from degradation of chitin induced by certain groups of bacteria that produce the enzymes deacetylase … In comparison, commercial poliglusam is derived from deacetylation of chitin contained in the shells of various sea crustaceans such as shrimps [L999].

  9. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides … GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.

  10. Drug

    VIT-100

    go.drugbank.com/drugs/DB05865
    Experimental

    In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control. … It is believed that similar effects would be seen in cells isolated from hypertrophic scars.